European Companies Search Engine
UK funding (£375,825): Enhancing the stability of RNA Therapeutics to improve their delivery and efficacy using universal non-toxic stabilisers Ukri1 Jun 2023 UK Research and Innovation, United Kingdom
Overview
Text
Enhancing the stability of RNA Therapeutics to improve their delivery and efficacy using universal non-toxic stabilisers
| Abstract | The speed with which SARS-CoV-2 vaccines were formulated, approved and rolled out to the UK public has been truly remarkable and unprecedented. In particular the development of mRNA-LNPs proved not only very fast but also highly effective compared with protein based vaccines, promising a new era of therapeutic/vaccine development in 'one hundred days or less'. Despite such rapid progress and promise, the development of mRNA-LNP technology has been a compromise between speed and utility; instability of the therapeutic/vaccine has proved to be a serious drawback requiring an ultra low temperature (-80°C) cold-chain which has directly increased the cost and complexity of vaccine rollout as well as limiting vaccination programs in high income countries. Furthermore because of the extreme fragility of mRNA, the therapeutic/vaccine dose varies depending on the integrity of the cold-chain. Based on results to date we believe we can overcome many of the manufacturing bottlenecks such as storage and dispensing, as well as transport at ambient temperature by developing a universal non-toxic stabiliser that protects the mRNA therapeutic/vaccine from the point of manufacturing through to stockpiling and transport to the clinic. We are confident that the use of our molecular stabilisers will radically change the market for RNA therapeutics/vaccines by allowing the manufacture, storage, transport and delivery of consistently intact and highly active mRNA therapeutic/vaccine treatments even in environments that are lacking a functional cold-chain and distribution system. |
| Category | Collaborative R&D |
| Reference | 10070430 |
| Status | Closed |
| Funded period start | 01/06/2023 |
| Funded period end | 31/05/2024 |
| Funded value | £375,825.00 |
| Source | https://gtr.ukri.org/projects?ref=10070430 |
Participating Organisations
| RNASSIST LIMITED |
£56,000.00 |
| CENTRE FOR PROCESS INNOVATION LIMITED |
£319,825.00 |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Rnassist Ltd., Cambridge.
The visualizations for "Rnassist Ltd. - UK funding (£375,825): Enhancing the stability of RNA Therapeutics to improve their delivery and efficacy using universal non-toxic stabilisers"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
